507PD - Clinical presentation, treatment, outcome, and prognostic factors of non-metastatic Ewing sarcoma family of tumors: A single centre experience of 3...

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Sarcoma
Topics Bone Sarcomas
Presenter Divya Khosla
Citation Annals of Oncology (2016) 27 (suppl_9): ix163-ix168. 10.1093/annonc/mdw597
Authors D. Khosla1, A.K. Pandey1, K. Dimri1, S. Garg2, R. Jindal2, S. Verma1
  • 1Radiotherapy & Oncology, Government Medical College and Hospital-GMCH Chandigarh, 160030 - Chandigarh/IN
  • 2Department Of Orthopaedics, Government Medical College and Hospital-GMCH Chandigarh, 160030 - Chandigarh/IN



Ewing sarcoma is the second most common bone tumor in children accounting for 2% of all childhood malignancies. The objective of this study was to determine the clinical presentation, treatment, outcome and prognostic factors for patients of non-metastatic Ewing sarcoma family of tumors (ESFT).


We retrospectively reviewed records of 35 patients of non-metastatic ESFT treated at our institute from 2008 to 2014. The records of all patients were analyzed to determine clinical presentation, treatment, survival and prognostic factors.


The median age of the patients was 16 years (range, 7 - 33 years) with male-to-female ratio of 1.69:1. Pain was the most common presenting symptom followed by localized swelling. The primary tumor sites included axial skeleton in 15 patients (42.9%) and extremities in 20 (57.1%). The median follow-up was 26.7 months (range, 7.27-95.13 months). The 5-year local control, event-free survival (EFS) and overall survival (OS) were 58.7%, 48.4%, 55.3%, respectively. At univariate analysis, tumor size ≥ 8 cm was significantly associated with inferior EFS (p = 0.03) and OS (p = 0.05). Age, gender, primary tumor site, central or peripheral location, local treatment modalities and margins did not have a significant effect on EFS and OS.


ESFT is an aggressive neoplasm with high rate of local recurrence and distant metastasis. Tumor size equal to more than 8 cm was significantly associated with inferior survival. Multimodality treatment comprising of aggressive chemotherapy, adequate surgical resection and radiotherapy should be considered to improve survival and outcome.

Clinical trial indentification

Legal entity responsible for the study



The study has been conducted by Department of Radiotherapy and Oncology. The authors declare no conflicts of interest or financial interests. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.


All authors have declared no conflicts of interest.